Total
0
Shares
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: AHI
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) reveals that Tinjoy Biotech’s WinScan app will launch in mid-August 2021
  • In April, the companies signed a marketing agreement for AHI’s BodyScan and FaceScan technology to be integrated into Winscan
  • Tinjoy was hoping to launch the app earlier, in line with the 618-sale held annually in China, but unfortunately did not meet this objective
  • On the market, AHI closed up 8.65 per cent at $1.13 per share

Advanced Human Imaging (AHI) has revealed that Tinjoy Biotech’s WinScan App will launch in mid-August 2021.

In April, the companies signed a marketing agreement for AHI’s BodyScan and FaceScan technology to be integrated into Winscan.

WinScan platform addresses wellness, preventative health and nutrition with the primary focus on identifying individuals at risk of chronic disease.

Tinjoy is a producer of supplements and traditional Chinese medicines based in Guangdong Province.

Tinjoy was hoping to launch the app earlier, in line with the 618-sale held annually in China, but unfortunately did not meet this objective.

Earlier this month, Tinjoy embarked on a pre-registration campaign using its call centre and new marketing platform, The Health Cube. This campaign was successful with 114,391 pre-registrations within a three-day period.

The soft launch of Health Cube was a test designed to find the concurrency and load capacity of the platform through existing Tinjoy customers. However the platform crashed after reaching several hundred thousand engagements.

Tinjoy did not anticipate such high volume concurrent transactions and forced the company to stop taking preregistration. This allowed the development team to make changes to the platform and upgrade the system to allow more transactions.

These upgrades have now been completed ahead of the launch in August.

AHI CEO Vlado Bosanac said to say he was pleased with the confirmation numbers “would be an understatement”.

“With an audience of more than 28,000,000 and a population of over a billion people within China, I am looking forward to seeing what the short-term launch will bring. China is a very health conscious and technology-friendly community,” Mr Bosanac said.

“The key steps from here are to launch the application and commence the consumer growth and acquisition plan Tinjoy are successfully executing on. With a target of one million users by Christmas 2021, we will do all we can to facilitate this with and for Tinjoy.”

Tinjoy Executive Director Russell Bateman said the delay was unfortunate but better for the product.

“The delay was unfortunate, but I believe we have a better product to offer our millions of consumers and preregistered parties,” he said.

“My first step will be to action the current preregistrations to downloads, and the marketing team will execute on next steps to continue the interest and growth we saw from the initial campaign to achieve the one million-user target we have undertaken with AHI.”

On the market, AHI closed up 8.65 per cent at $1.13 per share.

AHI by the numbers
More From The Market Herald

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.